Insmed reported $416.08M in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
DBV Technologies DBVT:US 21.3M 23.66M
Acelrx Pharmaceuticals ACRX:US $ 15.16M 6.66M
Alimera Sciences ALIM:US $ 7.86M 2.09M
Biomarin Pharmaceutical BMRN:US $ 619.8M 14.36M
Cytokinetics CYTK:US $ 93.63M 21.79M
Dynavax Technologies DVAX:US $ 249.09M 69.67M
Gilead Sciences GILD:US $ 7000M 2704M
Heron Therapeutics HRTX:US $ 48.61M 8.3M
Insmed INSM:US $ 416.08M 99.63M
Mirati Therapeutics MRTX:US $ 245.51M 47.91M
Novartis NVS:US $ 3625M 10227M
Ophthotech OPHT:US $ 141.11M 50.75M
Regeneron Pharmaceuticals REGN:US $ 3395.1M 49.4M
Sarepta Therapeutics SRPT:US $ 868.56M 365.31M
Seattle Genetics SGEN:US $ 364.87M 103.88M
Ultragenyx Pharmaceutical RARE:US $ 159.87M 5.88M
Vertex Pharmaceuticals VRTX:US $ 8702.2M 1102.1M